• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Schizophrenia market to rise to $7.3B

Report: Schizophrenia market to rise to $7.3B

November 15, 2016
CenterWatch Staff

The schizophrenia market across the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is set to rise from $6.4 billion in 2015 to $7.3 billion by 2025, registering a compound annual growth rate of 1.4%, according to research and consulting firm GlobalData.

The company’s latest report states that major drivers of this modest growth include the uptake of novel pipeline products that have been designed to satisfy unmet needs in the disease and development of long-acting injectable (LAI) formulations of atypical antipsychotics in order to improve patient compliance, a notable unmet need.

However, Christos Michaelides, Ph.D., GlobalData’s analyst covering Neurology and Ophthalmology, said, “While schizophrenia market growth will primarily be driven by the arrival of late-stage pipeline products, such as Minerva’s MIN-101 and Intra-Cellular Therapies’ ITI-007, both of which are directed towards the treatment of negative symptoms associated with schizophrenia, these symptoms will remain a significant unmet need in the space.”

Negative symptoms are conceptualized as an absence or diminution of normal emotional responses or thought processes, and include those such as apathy or asociality. Positive symptoms, on the other hand, are described as those that healthy individuals would not experience, including the reality distortion symptoms of hallucinations and delusions, as well as disorganized thoughts and behaviors.

Michaelides continued, “According to GlobalData’s primary research, there is no drug that can treat the negative symptoms of schizophrenia currently available. Several studies have found that avolition, social withdrawal, flat emotional affect, and speech and movement dysfunction have a greater negative impact on the quality of life and dysfunctional outcomes of schizophrenic individuals than positive symptoms of the disease. A drug addressing this is therefore urgent.

“Drugs such as MIN-101 and ITI-007, would mean this unmet need is somewhat satisfied during the forecast period. However, GlobalData believes that opportunity will remain for pharmaceutical companies to develop a drug that effectively targets negative symptoms of schizophrenia by 2025. Indeed, there is considerable R&D risk as past pipeline drugs that have attempted to target negative symptoms failed in clinical trials due to lack of efficacy.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing